Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 141,583 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 141,583 shares of the company’s stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.29, for a total value of $1,881,638.07. Following the completion of the transaction, the chief operating officer directly owned 516,610 shares in the company, valued at $6,865,746.90. The trade was a 21.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Julie Rubinstein also recently made the following trade(s):

• On Friday, March 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.96, for a total transaction of $247,017.60.
• On Monday, March 9th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.79, for a total transaction of $457,617.39.
• On Tuesday, March 10th, Julie Rubinstein sold 19,460 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.68, for a total value of $285,672.80.
• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.
• On Thursday, March 5th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $16.00, for a total value of $495,056.00.

Adaptive Biotechnologies Stock Up 5.8%

Shares of ADPT traded up $0.72 during trading hours on Friday, hitting $13.17. 3,902,529 shares of the company were exchanged, compared to its average volume of 1,832,300. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.68 and a fifty-two week high of $20.76. The company has a market cap of $2.03 billion, a price-to-earnings ratio of -32.92 and a beta of 2.19. The firm’s fifty day moving average is $16.55 and its 200 day moving average is $15.85.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million during the quarter, compared to the consensus estimate of $59.38 million. During the same quarter in the previous year, the firm earned ($0.23) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% compared to the same quarter last year. Analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Hedge Funds Weigh In On Adaptive Biotechnologies

A number of institutional investors have recently added to or reduced their stakes in the stock. AQR Capital Management LLC increased its stake in shares of Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Adaptive Biotechnologies by 4.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after buying an additional 2,914 shares during the last quarter. Caxton Associates LLP acquired a new stake in Adaptive Biotechnologies during the 1st quarter worth approximately $93,000. Envestnet Asset Management Inc. acquired a new stake in Adaptive Biotechnologies during the 2nd quarter worth approximately $467,000. Finally, Savant Capital LLC grew its holdings in Adaptive Biotechnologies by 15.4% during the 2nd quarter. Savant Capital LLC now owns 39,665 shares of the company’s stock worth $462,000 after acquiring an additional 5,305 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have recently weighed in on ADPT shares. JPMorgan Chase & Co. upped their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a report on Friday, February 6th. Guggenheim boosted their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Wall Street Zen cut Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. Finally, Morgan Stanley began coverage on Adaptive Biotechnologies in a report on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Adaptive Biotechnologies presently has an average rating of “Moderate Buy” and an average target price of $18.25.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.